摘要
肺炎克雷伯菌(Klebsiella pneumoniae,KP)是医院感染的重要病原菌,其临床分离率高,致病性强,碳青霉烯类抗菌药物曾作为耐药革兰阴性菌治疗的最后一道防线,但随着其在临床的广泛应用,近年碳青霉烯类耐药肺炎克雷伯菌逐年增多,并且在很多国家和地区出现了暴发流行的趋势,使得近年对碳青霉烯耐药肺炎克雷伯菌的研究多聚焦于分子耐药机制、分子流行病学特点与临床有效抗菌药物选择等方面。笔者通过对近年来碳青霉烯耐药肺炎克雷伯菌分子特征及抗菌药物活性相关研究文献进行综述,旨在明确碳青霉烯耐药肺炎克雷伯菌分子特征研究现状,探讨其分子特征与抗菌药物活性是否存在的相互影响,以期为临床掌握碳青霉烯耐药肺炎克雷伯菌暴发流行菌株的分子特征,寻找出有效抗菌药物治疗碳青霉烯耐药肺炎克雷伯菌感染提供理论依据,同时为探讨碳青霉烯耐药肺炎克雷伯菌不同分子特征与抗菌药物活性相关性研究奠定理论基础。
Klebsiella pneumoniae, an important nosocomial infection pathogen, has high rate of clinical isolates. Carbapenems a- gents is stable for the majority fllactamase initially, but with the broadly use of carbapenems agents, carbapenem resistant Klebsiella pneumoniae（CRKP） appear in hospital as a results, which result in the antibactic invalidation. With the CRKP rapiding growth in some area, the contents of the relevant literature review, in this article, the related literature content of the CRKP mechanism of drug resistance, molecular epidemiology and clinical antibiotic selection is reviewed, aims to explain the interaction between CRKP molecu- lar characteristics and antimicrobial activity, also to provide theoretical basis for the more rational use of antimicrobial agents in the treatment of CRKP infection, and to investigate the CRKP different molecular mechanisms and antimicrobial activity relationship studies lay the theoretical foundation.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2016年第5期346-352,共7页
Chinese Pharmaceutical Journal
基金
"十二五"国家科技重大专项基金资助项目(2012ZX09303004-002)
解放军总医院苗圃基金面上基金资助项目(15KMM51)
关键词
肺炎克雷伯菌
碳青霉烯耐药
分子特征
抗菌药物活性
Klebsiella pneumonia
carbapenem resistant
molecular characteristic
antimicrobial activity
